ArticleThe New England journal of medicine2022
Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
Abstract readLetter
In one paragraph
Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 312 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
312citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
312 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antibody titers of individuals vaccinated for COVID-19: A systematic review.Journal of biosciences · 2023Pooled it
- Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma.Annals of internal medicine · 2022Guideline
- Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.EBioMedicine · 2025Trial
- Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.Frontiers in immunology · 2025Trial
- Trial
- Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.The Journal of clinical investigation · 2022Trial
- Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.Cell reports. Medicine · 2022Trial
- Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.The Lancet. Respiratory medicine · 2022Trial
- Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.Journal of medical virology · 2026Article
- Longitudinal Antibody Dynamics Following SARS-CoV-2 Viral-Vectored and mRNA Booster Vaccination in Ghanaian Adults.Vaccines · 2026Article
- Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Structural and functional dissection of neutralisation differences among SARS-CoV-2 variants using antigenicity prediction and CR3022 binding analysis.Frontiers in immunology · 2026Article
- Article
- A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023.Communications medicine · 2025Review
- Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variants.Scientific reports · 2025Article
- Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunization.Science immunology · 2025Article
- Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity.PLoS pathogens · 2025Article
252 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
12 authors.
Fabian SchmidtRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Frauke MueckschRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Yiska WeisblumRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Justin Da SilvaRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Eva BednarskiRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Alice ChoRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Zijun WangRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Christian GaeblerRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Marina CaskeyRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Michel C NussenzweigRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Theodora HatziioannouRockefeller University, New York, NY pbieniasz@rockefeller.edu.
Paul D BieniaszRockefeller University, New York, NY pbieniasz@rockefeller.edu.ORCID 0000-0002-2368-3719
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$26.0MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MDiscovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9MHoward Hughes Medical InstituteNational Institute of Allergy and Infectious Diseases 2U19AI111825National Institute of Allergy and Infectious Diseases P01-AI138398-S1National Institute of Allergy and Infectious Diseases R01AI501111National Institute of Allergy and Infectious Diseases R01AI78788National Institute of Allergy and Infectious Diseases R37AI64003NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI078788NIAID NIH HHS R37 AI064003NIAID NIH HHS U19 AI111825
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansImmunogenicity, VaccineSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.